In transgenic mouse models, AXL gene deletion increases T-cell infiltration in the tumor microenvironment by up to 20 times, while making tumor cells 50 times more sensitive to radiotherapy and immune checkpoint therapy (112). Here, AXL is linked to neoplasm.